Nadia Waheed Sells 3,510 Shares of Ocular Therapeutix (NASDAQ:OCUL) Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Nadia Waheed sold 3,510 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $7.74, for a total transaction of $27,167.40. Following the completion of the transaction, the insider owned 314,907 shares in the company, valued at $2,437,380.18. This trade represents a 1.10% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Nadia Waheed also recently made the following trade(s):

• On Thursday, February 12th, Nadia Waheed sold 7,863 shares of Ocular Therapeutix stock. The stock was sold at an average price of $9.04, for a total transaction of $71,081.52.

Ocular Therapeutix Price Performance

Shares of NASDAQ OCUL opened at $9.50 on Thursday. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $2.07 billion, a PE ratio of -6.60 and a beta of 0.90. The firm has a fifty day simple moving average of $10.45 and a 200 day simple moving average of $11.61. Ocular Therapeutix, Inc. has a twelve month low of $5.78 and a twelve month high of $16.44.

Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $13.25 million during the quarter, compared to the consensus estimate of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business’s revenue was down 22.4% compared to the same quarter last year. During the same period last year, the business posted ($0.29) EPS. On average, sell-side analysts forecast that Ocular Therapeutix, Inc. will post -0.98 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Citigroup reissued an “outperform” rating on shares of Ocular Therapeutix in a research note on Tuesday, February 17th. Needham & Company LLC decreased their price target on shares of Ocular Therapeutix from $20.00 to $18.00 and set a “buy” rating for the company in a research note on Friday, February 20th. Chardan Capital reiterated a “buy” rating and set a $21.00 price objective on shares of Ocular Therapeutix in a report on Wednesday, February 18th. Finally, Wall Street Zen raised shares of Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Saturday, February 7th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $23.78.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Millennium Management LLC increased its position in shares of Ocular Therapeutix by 3,136.1% during the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock worth $45,073,000 after acquiring an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. lifted its position in Ocular Therapeutix by 2,003.2% in the 3rd quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock valued at $40,032,000 after acquiring an additional 3,261,619 shares in the last quarter. Avoro Capital Advisors LLC boosted its stake in Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock valued at $119,822,000 after purchasing an additional 2,850,000 shares during the last quarter. Vanguard Group Inc. increased its holdings in Ocular Therapeutix by 26.3% during the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock worth $140,523,000 after purchasing an additional 2,411,953 shares in the last quarter. Finally, Janus Henderson Group PLC raised its stake in shares of Ocular Therapeutix by 106.5% in the fourth quarter. Janus Henderson Group PLC now owns 4,229,202 shares of the biopharmaceutical company’s stock worth $51,321,000 after purchasing an additional 2,180,702 shares during the last quarter. Institutional investors and hedge funds own 59.21% of the company’s stock.

Ocular Therapeutix News Summary

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: Director Richard L. Lindstrom bought 60,229 shares at ~$7.66 (a 32% increase in his stake) — a large, high‑visibility insider purchase that signals management confidence and provides direct buying support. SEC Filing – Lindstrom Form 4
• Positive Sentiment: Ocular will present detailed SOL‑1 data at upcoming meetings and attend investor conferences in March — these events are material catalysts: favorable clinical or commercial readthroughs could drive a sharp re‑rating. Company to Present SOL‑1 Data
• Neutral Sentiment: Recent quarterly results were mixed: EPS slightly beat consensus but revenue declined ~22% year‑over‑year — this keeps near‑term execution questions on the table and makes management commentary and the next report important. (Company filings and recent coverage)
• Neutral Sentiment: Institutional trading has seen modest inflows and new small positions from several advisers; institutional ownership remains meaningful (~59%), which can mute volatility but also anchor sentiment over time.
• Negative Sentiment: Several insiders (including Sanjay Nayak, Jeffrey Heier, Peter Kaiser, Pravin Dugel and Nadia Waheed) sold shares in late Feb at prices around $7.74–$8.28. Multiple, clustered insider sales can create bearish headlines and add supply pressure even if individual sales are for diversification/liquidity. Representative SEC filing for Pravin Dugel’s sale: Dugel Form 4
• Negative Sentiment: Short interest jumped ~27.8% in February to ~14.7M shares (~6.9% of shares outstanding) with a ~3.0 days‑to‑cover — higher short activity increases downside pressure and volatility, but also raises squeeze risk if upcoming catalysts surprise positively. (Short interest data reported Feb. 13)
• Negative Sentiment: Needham cut its price target to $18 (while keeping a buy) — a downward analyst adjustment that can weigh on sentiment among growth/biotech investors even as other firms remain constructive. Needham Lowers Price Target

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.